

Global Human Papillomavirus (HPV) Vaccines Market - 2025-2033

<https://marketpublishers.com/r/G8230F6758A2EN.html>

Date: May 2025

Pages: 180

Price: US\$ 4,350.00 (Single User License)

ID: G8230F6758A2EN

Abstracts

Global Human Papillomavirus (HPV) Vaccines Market – Industry Trends & Outlook

The global human papillomavirus (HPV) vaccine market size reached US\$ 3,043.19 Million in 2024 and is expected to reach US\$ 12,361.15 Million by 2033, growing at a CAGR of 16.9% during the forecast period 2025-2033.

HPV vaccines protect against infection with human papillomaviruses (HPV), a group of over 200 related viruses, more than 40 of which are transmitted through direct sexual contact. Among these, two types are responsible for genital warts, while about a dozen high-risk types can lead to cancers such as cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers.

Key drivers fueling market growth are the rising burden of HPV-related cancers, strong governmental and international support for vaccination, improved vaccine accessibility, and growing investments from pharmaceutical companies. Opportunities abound in emerging markets, the introduction of new vaccine formulations, and integration with broader adolescent health initiatives.

The scope of the market encompasses bivalent, tetravalent, and nonavalent vaccines, targeting prevention of cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers. North America continues to dominate the market, holding nearly half of the global share, while the Asia-Pacific region is poised for the fastest growth due to rising HPV-related cancer incidence and expanding immunization programs.

Industry outlook is optimistic, driven by increasing disease awareness, government initiatives, and global health partnerships. Trends shaping the market include innovation

in adjuvant technology, expanded focus on immunocompromised and LGBTQ+ populations, integration of vaccination with cancer screening, and the rise of community-based education programs.

Market insights highlight the rapid scale-up of both supply and demand, particularly in underserved regions, and the central role of HPV vaccination in comprehensive cancer control strategies. Industry reports consistently emphasize the importance of health equity, vaccine equity, and market-shaping efforts by organizations like Gavi, UNICEF, and WHO to improve supply, pricing, and access globally. Overall, the HPV vaccines market is set for sustained, impactful growth, underpinned by innovation, policy support, and a global commitment to reducing HPV-related disease burden.

Global Human Papillomavirus (HPV) Vaccines Market Dynamics: Drivers & Restraints

Rising Prevalence of Cervical Cancer

The rising prevalence of cervical cancer-now the fourth most common cancer in women globally, as per World Health Organization (WHO) data in March 2024, with around 660,000 new cases and 350,000 deaths in 2022-is a powerful driver for growth in the global human papillomavirus (HPV) vaccines market. This burden is especially acute in low- and middle-income countries (LMICs), which account for about 94% of cervical cancer deaths, and in regions such as sub-Saharan Africa, Central America, and South-East Asia, where incidence and mortality rates are highest.

The high incidence and mortality rates of cervical cancer, particularly in LMICs, have heightened awareness among governments, health organizations, and the public about the need for effective prevention. This has led to greater prioritization of HPV vaccination as a public health strategy. Countries with the highest cervical cancer rates-such as those in sub-Saharan Africa and South-East Asia-are increasingly introducing or scaling up HPV vaccination programs. As more LMICs add HPV vaccines to their national immunization schedules, the market for these vaccines continues to expand.

Accessibility and Supply Chain Issues

Accessibility and supply chain challenges have been persistent restraints in the global human papillomavirus (HPV) vaccines market, particularly impacting low- and middle-income countries (LMICs) where the burden of HPV-related diseases is highest.

Rapid increases in demand, driven by expanded vaccination programs, have outpaced

manufacturers' ability to scale up production, presenting extraordinary challenges for timely supply. Technology transfers to expand global manufacturing capacity have been limited, and the process of bringing new suppliers to market with WHO-prequalified products is slow.

Accessibility and supply chain issues have significantly limited the reach and impact of HPV vaccination programs worldwide. Addressing these barriers through increased manufacturing capacity, diversified suppliers, improved logistics, and sustained funding remains critical for achieving global cervical cancer prevention goals.

Global Human Papillomavirus (HPV) Vaccines Market - Segment Analysis

The global human papillomavirus (HPV) vaccine market is segmented based on type, gender, age group, indication, and region.

Indication:

The cervical cancer segment was valued at US\$ 1,668.33 million in 2024 and is estimated to reach US\$ 6,469.87 million by 2033, growing at a CAGR of 14.4% during the forecast period from 2025-2033

Human papillomavirus (HPV) is a highly prevalent sexually transmitted virus, infecting over 80% of individuals by age 45. While most HPV infections are asymptomatic, the virus is responsible for a range of cancers, most notably the majority of cervical cancer. As per World Health Organization (WHO) data in 2022, there were an estimated 661,000 new cases of cervical cancer and more than 348,000 related deaths worldwide, making it the fourth leading cause of both cancer incidence and mortality among women. More than 90% of cervical cancer deaths occur in low- and middle-income countries, highlighting significant global health disparities.

This segment is the primary focus of national immunization programs and global health initiatives such as those led by the World Health Organization (WHO), GAVI, and UNICEF, which prioritize vaccination of adolescent girls to prevent cervical cancer.

The high disease burden, especially in low- and middle-income countries (LMICs) where regular screening is limited, further intensifies the demand for prophylactic HPV vaccines. Additionally, increasing awareness, inclusion of HPV vaccines in school-based immunization programs, and the growing availability of low-cost domestic vaccines from manufacturers in India and China have accelerated market penetration.

Technological advancements and the introduction of nonavalent vaccines with broader strain coverage have also contributed to improved protection against cervical cancer and its associated precancerous lesions, strengthening the growth trajectory of this segment globally.

Global Human Papillomavirus (HPV) Vaccines Market - Geographical Analysis

The North America human papillomavirus (HPV) vaccine market was valued at US\$ 1,143.64 million in 2024 and is estimated to reach US\$ 4,819.32 million by 2033, growing at a CAGR of 15.3% during the forecast period from 2025-2033

The North America human papillomavirus (HPV) vaccines market is driven by several key factors that collectively support its growth and leadership in the global landscape. A primary driver is the high burden of HPV-related cancers, including cervical, anal, and oropharyngeal cancers, which has heightened the urgency for preventive measures across the region.

Robust healthcare infrastructure and widespread access to medical services enable early screening and efficient vaccine delivery, while strong governmental and public health initiatives-such as school-based vaccination programs and awareness campaigns-have significantly increased vaccine uptake.

Additionally, frequent product launches, regulatory approvals, and expanded indications by leading market players-such as the approval of Gardasil 9 for broader age groups-promote market expansion and accessibility.

Investments in research and development, a favorable regulatory environment, and strategic collaborations between public and private sectors also contribute to the market's growth and resilience. Collectively, these drivers ensure that North America remains at the forefront of HPV vaccine adoption and innovation, supporting ongoing efforts to reduce the incidence and mortality of HPV-related diseases.

The Asia-Pacific human papillomavirus (HPV) vaccine market was valued at US\$ 605.23 million in 2024 and is estimated to reach US\$ 3,292.92 million by 2033, growing at a CAGR of 18.3% during the forecast period from 2025-2033

The Asia-Pacific HPV vaccines market is one of the fastest-growing regions globally. It includes major countries such as Japan, China, India, South Korea, Australia, and

Southeast Asian nations. The market is driven by rising awareness, government initiatives, and the increasing incidence of HPV-related cancers.

The incidence of cervical and other HPV-related cancers is increasing in Asia-Pacific, especially in countries with large populations like India and China. Japan has a significant focus on cervical cancer prevention due to its public health impact.

Many governments (including Japan, Australia, and China) have launched or expanded national immunization programs for HPV vaccination. Subsidies and school-based vaccination campaigns are boosting coverage.

Japan is a major market in the region. After a period of suspended recommendations, the government resumed proactive HPV vaccination in 2022, leading to a surge in vaccination rates. Japan's robust healthcare infrastructure and public health policies are expected to further drive market growth.

Global Human Papillomavirus (HPV) Vaccines Market - Competitive Landscape (Major Players)

Top companies in the human papillomavirus (HPV) vaccine market include Merck & Co., Inc., GSK plc, Wantai BioPharm., Walvax Biotechnology Co., Ltd., Serum Institute of India Pvt. Ltd., and Jiangsu Recbio Technology Co., Ltd., among others.

Global Human Papillomavirus (HPV) Vaccines Market - Competitive Landscape (Emerging Players)

Emerging companies in the human papillomavirus (HPV) vaccine market include DCVMN International, Shanghai Zerun Biotech Co., Ltd., Shanghai Bovax Biotechnology Co., Ltd., Jiangsu Recbio Technology Co., Ltd., Toragen, BlueSky Immunotherapies, Antiva Biosciences, Precigen, INOVIO Pharmaceuticals, and BioNTech SE, among others.

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Type
- 2.4. Snippet by Gender
- 2.5. Snippet by Age Group
- 2.6. Snippet by Indication
- 2.7. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Prevalence of Cervical Cancer
 - 3.1.1.2. Rising Vaccination Drives Against HPV
 - 3.1.1.3. XX
 - 3.1.2. Restraints
 - 3.1.2.1. Accessibility and Supply Chain Issues
 - 3.1.2.2. High Vaccine Cost and Affordability
 - 3.1.2.3. XX
 - 3.1.3. Opportunity
 - 3.1.3.1. Development of Advanced Vaccine Formulations
 - 3.1.3.2. XX
 - 3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand

- 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape
 - 4.3.1. North America
 - 4.3.2. Europe
 - 4.3.3. Asia Pacific
 - 4.3.4. Latin America
 - 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
- 4.5. Supply Chain Analysis
- 4.6. Patent Analysis
- 4.7. SWOT Analysis
- 4.8. Pipeline Analysis
- 4.9. Epidemiology Analysis
- 4.10. Unmet Needs and Gaps
- 4.11. Recommended Strategies for Market Entry and Expansion
- 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 4.13. Pricing Analysis and Price Dynamics
- 4.14. Key Opinion Leaders

5. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY TYPE

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 5.1.2. Market Attractiveness Index, By Type
- 5.2. Bivalent*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Quadrivalent
- 5.4. Nona valent

6. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY GENDER

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender
 - 6.1.2. Market Attractiveness Index, By Gender
- 6.2. Female*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Male

7. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY AGE GROUP

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

7.1.2. Market Attractiveness Index, By Age Group

7.2. Children*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Adults

8. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY INDICATION

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8.1.2. Market Attractiveness Index, By Indication

8.2. Cervical Cancer*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Vaginal Cancer

8.4. Anal Cancer

8.5. Others

9. HUMAN PAPILLOMAVIRUS (HPV) VACCINES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.7.1. U.S.

9.2.7.2. Canada

9.2.7.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.7.1. Germany

9.3.7.2. UK

9.3.7.3. France

9.3.7.4. Spain

9.3.7.5. Italy

9.3.7.6. Rest of Europe

9.4. Asia-Pacific

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.7.1. China

9.4.7.2. India

9.4.7.3. Japan

9.4.7.4. South Korea

9.4.7.5. Rest of Asia-Pacific

9.5. South America

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.7.1. Brazil

9.5.7.2. Argentina

9.5.7.3. Rest of South America

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

10.1. Competitive Overview and Key Market Players

10.2. Market Share Analysis and Positioning Matrix

10.3. Strategic Partnerships, Mergers & Acquisitions

10.4. Key Developments in Product Portfolios and Innovations

10.5. Company Benchmarking

11. COMPANY PROFILES

Major Players

11.1. Merck & Co., Inc.

11.1.1. Company Overview

11.1.2. Product Portfolio

11.1.2.1. Product Description

11.1.2.2. Product Key Performance Indicators (KPIs)

11.1.2.3. Historic and Forecasted Product Sales

11.1.2.4. Product Sales Volume

11.1.3. Financial Overview

11.1.3.1. Company Revenue

11.1.3.2. Geographical Revenue Shares

11.1.3.3. Revenue Forecasts

11.1.4. Key Developments

11.1.4.1. Mergers & Acquisitions

11.1.4.2. Key Product Development Activities

11.1.4.3. Regulatory Approvals, etc.

11.1.5. SWOT Analysis

11.2. GSK plc.

11.3. Wantai BioPharm.

11.4. Walvax Biotechnology Co., Ltd.

- 11.5. Serum Institute of India Pvt. Ltd.
- Emerging Players
- 11.6. DCVMN International.
- 11.7. Shanghai Zerun Biotech Co., Ltd.
- 11.8. Shanghai Bovax Biotechnology Co., Ltd.
- 11.9. Jiangsu Recbio Technology Co., Ltd.
- 11.10. Toragen
- 11.11. BlueSky Immunotherapies
- 11.12. Antiva Biosciences
- 11.13. Precigen
- 11.14. INOVIO Pharmaceuticals
- 11.15. BioNTech SE
- LIST NOT EXHAUSTIVE

12. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 12.1. Data Collection Methods
- 12.2. Data Triangulation
- 12.3. Forecasting Techniques
- 12.4. Data Verification and Validation

13. APPENDIX

- 13.1. About Us and Services
- 13.2. Contact Us

List Of Tables

LIST OF TABLES

Table 1 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2025, 2029 & 2033 (US\$ Million)

Table 2 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2025, 2029 & 2033 (US\$ Million)

Table 3 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2025, 2029 & 2033 (US\$ Million)

Table 4 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US\$ Million)

Table 5 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)

Table 6 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2025, 2029 & 2033 (US\$ Million)

Table 7 Global Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US\$ Million)

Table 8 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2025, 2029 & 2033 (US\$ Million)

Table 9 Global Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US\$ Million)

Table 10 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2025, 2029 & 2033 (US\$ Million)

Table 11 Global Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US\$ Million)

Table 12 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2025, 2029 & 2033 (US\$ Million)

Table 13 Global Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US\$ Million)

Table 14 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)

Table 15 Global Human Papillomavirus (HPV) Vaccines Market Value, By Region, 2022-2033 (US\$ Million)

Table 16 North America Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US\$ Million)

Table 17 North America Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US\$ Million)

Table 18 North America Human Papillomavirus (HPV) Vaccines Market Value, By Age

Group, 2022-2033 (US\$ Million)

Table 19 North America Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US\$ Million)

Table 20 North America Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US\$ Million)

Table 21 South America Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US\$ Million)

Table 22 South America Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US\$ Million)

Table 23 South America Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US\$ Million)

Table 24 South America Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US\$ Million)

Table 25 South America Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US\$ Million)

Table 26 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US\$ Million)

Table 27 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US\$ Million)

Table 28 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US\$ Million)

Table 29 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US\$ Million)

Table 30 Europe Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US\$ Million)

Table 31 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US\$ Million)

Table 32 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US\$ Million)

Table 33 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US\$ Million)

Table 34 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US\$ Million)

Table 35 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US\$ Million)

Table 36 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Type, 2022-2033 (US\$ Million)

Table 37 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Gender, 2022-2033 (US\$ Million)

Table 38 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Age Group, 2022-2033 (US\$ Million)

Table 39 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Indication, 2022-2033 (US\$ Million)

Table 40 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, By Country, 2022-2033 (US\$ Million)

Table 41 Merck & Co., Inc.: Overview

Table 42 Merck & Co., Inc.: Product Portfolio

Table 43 Merck & Co., Inc.: Key Developments

Table 44 GSK plc.: Overview

Table 45 GSK plc.: Product Portfolio

Table 46 GSK plc: Key Developments

Table 47 Wantai BioPharm.: Overview

Table 48 Wantai BioPharm.: Product Portfolio

Table 49 Wantai BioPharm.: Key Developments

Table 50 Walvax Biotechnology Co., Ltd.: Overview

Table 51 Walvax Biotechnology Co., Ltd.: Product Portfolio

Table 52 Walvax Biotechnology Co., Ltd.: Key Developments

Table 53 Serum Institute of India Pvt. Ltd.: Overview

Table 54 Serum Institute of India Pvt. Ltd.: Product Portfolio

Table 55 Serum Institute of India Pvt. Ltd.: Key Developments

Table 56 DCVMN International.: Overview

Table 57 DCVMN International.: Product Portfolio

Table 58 DCVMN International.: Key Developments

Table 59 Shanghai Zerun Biotech Co., Ltd.: Overview

Table 60 Shanghai Zerun Biotech Co., Ltd.: Product Portfolio

Table 61 Shanghai Zerun Biotech Co., Ltd.: Key Developments

Table 62 Shanghai Bovax Biotechnology Co., Ltd.: Overview

Table 63 Shanghai Bovax Biotechnology Co., Ltd.: Product Portfolio

Table 64 Shanghai Bovax Biotechnology Co., Ltd.: Key Developments

Table 65 Jiangsu Recbio Technology Co., Ltd.: Overview

Table 66 Jiangsu Recbio Technology Co., Ltd.: Product Portfolio

Table 67 Jiangsu Recbio Technology Co., Ltd.: Key Developments

Table 68 Toragen: Overview

Table 69 Toragen: Product Portfolio

Table 70 Toragen: Key Developments

Table 71 BlueSky Immunotherapies: Overview

Table 72 BlueSky Immunotherapies: Product Portfolio

Table 73 BlueSky Immunotherapies: Key Developments

Table 74 Antiva Biosciences: Overview

Table 75 Antiva Biosciences: Product Portfolio

Table 76 Antiva Biosciences: Key Developments

Table 77 Precigen: Overview

Table 78 Precigen: Product Portfolio

Table 79 Precigen: Key Developments

Table 80 INOVIO Pharmaceuticals: Overview

Table 81 INOVIO Pharmaceuticals: Product Portfolio

Table 82 INOVIO Pharmaceuticals: Key Developments

Table 83 BioNTech SE: Overview

Table 84 BioNTech SE: Product Portfolio

Table 85 BioNTech SE: Key Developments

List Of Figures

LIST OF FIGURES

Figure 1 Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 2 Global Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)

Figure 3 Global Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)

Figure 4 Global Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)

Figure 5 Global Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)

Figure 6 Global Human Papillomavirus (HPV) Vaccines Market Share, By Region, 2024 & 2033 (%)

Figure 7 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Type, 2023-2033 (%)

Figure 8 Fibrolamellar HCC Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 9 Sarcomatoid HCC Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 10 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Gender, 2023-2033 (%)

Figure 11 Immunotherapy Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 12 Targeted therapy Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 13 Radiation Therapy Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 14 Surgery Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 15 Ablation and Embolization Therapies Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 16 Other Gender in Global Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 17 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Age Group, 2023-2033 (%)

Figure 18 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By

Indication, 2023-2033 (%)

Figure 19 Global Human Papillomavirus (HPV) Vaccines Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 20 North America Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 21 North America Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)

Figure 22 North America Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)

Figure 23 North America Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)

Figure 24 North America Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)

Figure 25 North America Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)

Figure 26 South America Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 27 South America Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)

Figure 28 South America Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)

Figure 29 South America Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)

Figure 30 South America Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)

Figure 31 South America Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)

Figure 32 Europe Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 33 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)

Figure 34 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)

Figure 35 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)

Figure 36 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)

Figure 37 Europe Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)

Figure 38 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 39 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)

Figure 40 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)

Figure 41 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)

Figure 42 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)

Figure 43 Asia-Pacific Human Papillomavirus (HPV) Vaccines Market Share, By Country, 2024 & 2033 (%)

Figure 44 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 45 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Type, 2024 & 2033 (%)

Figure 46 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Gender, 2024 & 2033 (%)

Figure 47 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Age Group, 2024 & 2033 (%)

Figure 48 Middle East and Africa Human Papillomavirus (HPV) Vaccines Market Share, By Indication, 2024 & 2033 (%)

Figure 49 Merck & Co., Inc.: Financials

Figure 50 GSK plc.: Financials

Figure 51 Wantai BioPharm.: Financials

Figure 52 Walvax Biotechnology Co., Ltd.: Financials

Figure 53 Serum Institute of India Pvt. Ltd.: Financials

Figure 54 DCVMN International.: Financials

Figure 55 Shanghai Zerun Biotech Co., Ltd.: Financials

Figure 56 Shanghai Bovax Biotechnology Co., Ltd.: Financials

Figure 57 Jiangsu Recbio Technology Co., Ltd.: Financials

Figure 58 Toragen: Financials

Figure 59 BlueSky Immunotherapies: Financials

Figure 60 Antiva Biosciences: Financials

Figure 61 Precigen: Financials

Figure 62 INOVIO Pharmaceuticals: Financials

Figure 63 BioNTech S: Financials

I would like to order

Product name: Global Human Papillomavirus (HPV) Vaccines Market - 2025-2033

Product link: <https://marketpublishers.com/r/G8230F6758A2EN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8230F6758A2EN.html>